Projects per year
Personal profile
Biography
I am a haematologist and haemato-oncologist, managing all blood disorders including general haematology, malignant haematology (eg lymphoma, leukaemia, myeloma), bleeding disorders, venous thromboembolic disease (blood clots) and obstetric haematology.
I am involved in clinical trials and translational research, with an interest in myelodysplastic syndrome (MDS), a pre-leukaemia disease, running Australia wide clinical trials in this condition.
The Blood Unit is a Specialist Haematology Group Practice at Cabrini, for more detailed information on our practice, please visit: http://www.thebloodunit.com.au/
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Research area keywords
- Myelodysplastic syndrome
- Blood disorders
- Malignant Haematology
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Kenealy, M. (Primary Chief Investigator (PCI))
16/11/23 → 15/11/25
Project: Research
-
An open-label, multi-center, long-term extension study of Zanubrutinib (BGB-3111) in patients with B-cell malignancies
Kenealy, M. (Primary Chief Investigator (PCI)) & Baker, E. (Project Manager)
13/02/20 → 31/12/25
Project: Research
-
A phase 3, open-label, randomised study to compare the efficacy and safety of luspatercept (Ace-536) versus epoetin alfa for the treatment of anaemia due to Ipss-R very low, low or intermediate risk myelodysplastic syndromes (MDS) in ESA naive subjects who require red blood cell transfusions [ACE-536-MDS-002]
Kenealy, M. (Primary Chief Investigator (PCI)) & Baker, E. (Project Manager)
20/12/18 → 1/06/27
Project: Research
-
A Phase I/II, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics and efficacy of GB261 in patients with relapsed or refractory B-cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukaemia.
Kenealy, M. (Primary Chief Investigator (PCI)) & Spence, A. (Project Manager)
21/02/22 → 31/12/24
Project: Research
-
A first-in-human, Phase I/II, open-label study to evaluate the safety, tolerability, pharmacokinetics and preliminary antitumour activity of EMB-06 in patients with recurrent or refractory multiple myeloma
Kenealy, M. (Primary Chief Investigator (PCI)) & Lai, L. H. (Project Manager)
20/09/21 → 31/12/24
Project: Research
-
Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia
McQuilten, Z. K., Busija, L., Seymour, J. F., Stanworth, S., Wood, E. M., Kenealy, M., Weinkove, R. & on behalf of the Australasian Leukaemia and Lymphoma Group (ALLG), 23 Feb 2022, In: Leukemia and Lymphoma. 63, 3, p. 676-683 8 p.Research output: Contribution to journal › Article › Research › peer-review
5 Citations (Scopus) -
A feasibility and acceptability study of an adaptation of the Mindful Self-Compassion program for adult cancer patients
Brooker, J., Julian, J., Millar, J., Prince, H. M., Kenealy, M., Herbert, K., Graham, A., Smith, R., Kissane, D., Taylor, K., Frydenberg, M., Porter, I., Fletcher, J., Haines, I. & Burney, S., Apr 2020, In: Palliative and Supportive Care. 18, 2, p. 130-140 11 p.Research output: Contribution to journal › Article › Research › peer-review
31 Citations (Scopus) -
Complete remission of Waldenström's associated generalized crystal-storing histiocytosis of IgM lambda subtype with bortezomib-based combination chemotherapy
Baird, S. M., Kenealy, M. K. & Hoy, R., 2 Nov 2015, In: Leukemia and Lymphoma. 56, 11, p. 3233-3235 3 p.Research output: Contribution to journal › Letter › Other › peer-review
5 Citations (Scopus) -
Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy
Carney, D. A., Westerman, D. A., Tam, C. S., Milner, A., Prince, H. M., Kenealy, M., Wolf, M., Januszewicz, E. H., Ritchie, D., Came, N. & Seymour, J. F., Dec 2010, In: Leukemia. 24, 12, p. 2056-2062 7 p.Research output: Contribution to journal › Article › Research › peer-review
100 Citations (Scopus) -
Treatment-related myelodysplasia following fludarabine combination chemotherapy
Tam, C. S., Seymour, J. F., Prince, H. M., Kenealy, M., Wolf, M., Januszewicz, E. H. & Westerman, D., Nov 2006, In: Haematologica. 91, 11, p. 1546-1550 5 p.Research output: Contribution to journal › Article › Research › peer-review
71 Citations (Scopus)